The FDA called for stronger warnings on the labels of Johnson & Johnson's Remicade, Abbott Laboratories' Humira, Amgen and Wyeth's Enbrel and UCB's Cimzia to inform patients about the risk of developing histoplasmosis, a harmful fungal infection. The drugs, also known as tumor necrosis factor blockers, are approved in the U.S. for treating rheumatoid arthritis and Crohn's disease. The drugmakers are cooperating with the FDA for compliance, an agency official said.

Related Summaries